Inactive Instrument

Enzymatica AB (publ) Share Price OTC Markets

EZYMF

SE0003943620

Valuation : Enzymatica AB (publ)

Market Cap	439M 379M 355M 324M 610M 41.99B 612M 4.21B 1.64B 21.2B 1.65B 1.61B 70.28B	P/E 2024	-5.73x	P/E 2025	-8.89x
Enterprise Value	407M 351M 329M 300M 566M 38.92B 568M 3.9B 1.52B 19.65B 1.53B 1.5B 65.15B	EV / Sales 2024	5.88x	EV / Sales 2025	7.96x
Free-Float	56.66%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Enzymatica AB (publ)

08-27	Enzymatica expands group management with two executives	FW
07-20	Enzymatica CFO Holger Lembrér buys shares for 110,000 kronor	FW
07-16	Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-16	Enzymatica cut revenue, but the loss also narrowed	FW
06-24	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article	CI
06-24	Scientific paper on Enzymatica's Berlin II study receives an Expression of Concern, update	FW
06-23	Study of Enzymatica's cold spray Coldzyme gets a warning flag	FW
06-09	Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026	CI
06-09	Enzymatica appoints new Head of Marketing and Sales to drive Coldzyme growth in the Nordics	FW
04-28	Enzymatica Q1 operating loss narrows to SEK 13.6 million	RE
04-28	Enzymatica narrows losses	FW
04-28	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Enzymatica Marketing Executive sells shares worth over SEK 0.1 million	FW

More news

Analysts' recommendations : Enzymatica AB (publ)

19/07/24	Penser lowers motivated value for Enzymatica - raises required return to reflect risk	FW
26/04/24	Redeye lowers motivated value for Enzymatica to SEK 5.5 (6.0)	FW
20/02/24	Penser lowers Enzymaticas' motivated value	FW
08/11/23	Penser lowers motivated value for Enzymatica	FW
08/11/23	Redeye lowers motivated value for Enzymatica to SEK 6.0 (6.5)	FW

More recommendations

Press Releases : Enzymatica AB (publ)

08-27	Enzymatica strengthens its management team with commercial and scientific expertise	AQ
07-16	Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization	AQ
06-24	The evidence base for ColdZyme remains unchanged – PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme	AQ
06-09	Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics	AQ
06-08	Enzymatica : partners with Unibet Rose Rockets to put ColdZyme in the Giro d’Italia race routine	PU

More press releases

Managers and Directors : Enzymatica AB (publ)

Manager	Title	Age	Since
Sana Alajmovic CEO	Chief Executive Officer	-	31/01/2026
Holger Lembrér DFI	Director of Finance/CFO	-	12/04/2026
Bjarki Stefánsson CTO	Chief Tech/Sci/R&D Officer	-	26/08/2026

Director	Title	Age	Since
Gudmundur Palmason CHM	Chairman	58	14/02/2016
Bengt Baron CHM	Chairman	64	18/12/2016
Mats K. Andersson BRD	Director/Board Member	71	18/12/2016

More insiders

Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

Employees

Sector

Pharmaceuticals

Calendar

10-29 Earnings release - Q3 2026

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZYMATICA AB (PUBL)	-9.63%	-50.94%	-	-	45.84M
ELI LILLY AND COMPANY	-0.13%	-6.44%	+60.47%	+112.05%	1,047B
JOHNSON & JOHNSON	+0.85%	-0.81%	+52.77%	+63.15%	646B
ABBVIE INC.	-1.03%	-3.58%	+22.87%	+73.29%	451B
ROCHE HOLDING AG	-1.46%	-4.50%	+37.43%	+38.41%	355B
NOVARTIS AG	-0.72%	-2.89%	+21.86%	+36.79%	291B
ASTRAZENECA PLC	-1.19%	-2.21%	+1.35%	+12.29%	252B
AMGEN INC.	-1.05%	-1.57%	+51.40%	+68.55%	234B
NOVO NORDISK A/S	+0.08%	-1.78%	-17.64%	-54.29%	203B
GILEAD SCIENCES, INC.	-2.14%	-0.30%	+29.42%	+89.10%	181B
Average	-1.65%	-2.68%	+28.88%	+48.82%	406.59B
Weighted average by Cap.	-0.48%	-3.46%	+38.66%	+65.51%

	2024	2025
Net sales	45.58M 39.27M 36.82M 33.61M 63.32M 4.36B 63.52M 437M 170M 2.2B 171M 167M 7.29B	53.9M 46.45M 43.55M 39.75M 74.89M 5.15B 75.13M 517M 202M 2.6B 202M 198M 8.62B
Net income	-53.18M -45.82M -42.96M -39.22M -73.89M -5.08B -74.12M -510M -199M -2.57B -200M -195M -8.51B	-51.89M -44.71M -41.92M -38.27M -72.09M -4.96B -72.32M -497M -194M -2.5B -195M -191M -8.3B
Net Debt	-73.01M -62.91M -58.99M -53.85M -101M -6.98B -102M -700M -273M -3.52B -274M -268M -11.68B	-32.11M -27.67M -25.94M -23.68M -44.61M -3.07B -44.76M -308M -120M -1.55B -121M -118M -5.14B

Enzymatica AB (publ) Share Price OTC Markets

Stocks

EZYMF

SE0003943620

Pharmaceuticals

Valuation : Enzymatica AB (publ)

Latest news : Enzymatica AB (publ)

Analysts' recommendations : Enzymatica AB (publ)

Press Releases : Enzymatica AB (publ)

Quotes and Performance

Managers and Directors : Enzymatica AB (publ)

Other Pharmaceuticals

Financials

Company Profile